FDA Gives Go Ahead for Actavis’ Irinotecan Hydrochloride Injection

MORRISTOWN, NJ--(Marketwire - March 14, 2008) - Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection, a cancer drug, from the US Food & Drug Administration (FDA).

MORE ON THIS TOPIC